Matsuoka H, et al. - Researchers conducted a multicenter, randomized, double-blind, placebo-controlled trial at 12 specialized palliative care services in Japan examining the efficacy of duloxetine for cancer-related neuropathic pain (CNP) nonresponsive or intolerant to opioid-pregabalin combination therapy. Seventy patients with CNP average pain scores (Brief Pain Inventory–Item 5) ≥ 4 in the previous 24 hours and nonresponsive or intolerant to opioid-pregabalin combination therapy, were administered duloxetine 20 mg/day (Group D) titrated to 40 mg/day or placebo (Group P) for 10 days. In Group D and Group P, 44.1% (n = 15) vs 18.2% (n = 6), respectively showed clinically meaningful pain improvement (≥30%); pain reduction ≥ 50% was reported in 32.4% (n = 11) vs 3.0% (n = 1) of patients in Groups D and P, respectively. These outcomes suggest that in these patients, pain may be alleviated with the addition of duloxetine to opioid-pregabalin combination therapy.